Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca, Datroway
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
China, AstraZeneca
AstraZeneca overhauls management of its China division, FT reports
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times reported on Friday, citing two people with direct knowledge of the matter.
AstraZeneca overhauls management of its scandal-hit China division
AstraZeneca has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of its president in the country.
AstraZeneca said to have changed management of its China unit
AstraZeneca (NASDAQ:AZN) has changed several key management positions in its China business as the Anglo-Swedish drugmaker looks to boost its sales following the recent detention of its President Leon Wang and several other scandals,
1h
AZN INVESTOR ALERT: AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
If you suffered substantial losses and wish to serve as lead plaintiff of the AstraZeneca class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or ...
9h
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
FiercePharma
12h
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
1d
Harnessing AI and data science to discover life-changing medicines at AstraZeneca
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
BioSpace
11h
AstraZeneca Gets Full FDA Approval for CMS-Selected Lymphoma Treatment
The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...
1d
AstraZeneca rises Thursday, outperforms market
Shares of AstraZeneca PLC AZN rallied 1.84% to £108.44 Thursday, on what proved to be an all-around positive trading session ...
News Medical on MSN
1d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina Maker
Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
11h
The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
2d
AstraZeneca rises Wednesday, still underperforms market
Shares of AstraZeneca PLC AZN inched up 0.17% to £106.48 Wednesday, on what proved to be an all-around positive trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
China
United States
Calquence
NASDAQ
breast cancer
Feedback